Table 3

Cytotoxicity of paclitaxel and cisplatin alone and in combination with ALC on different human tumor cell lines (IC50 as μg/ml ± SD)

Cells were treated for 2 h with paclitaxel or cisplatin at different concentrations ± 200 μg/ml ALC. Then the drugs were removed and fresh medium added. After 72 h cytotoxicity was evaluated with the sulphorodamine B test.

Tumor cell lineALCDrugsALC + drugs
Breast cancer (MDA-MB435)
 Paclitaxel>2000.005 ± 0.00020.005 ± 0.0002
 Cisplatin>2006.2 ± 1.06.2 ± 0.09
Colon cancer (HT-29)
 Paclitaxel>2000.01 ± 0.0010.01 ± 0.001
 Cisplatin>2005.5 ± 0.044.3 ± 0.02
Prostate cancer (PC3)
 Paclitaxel>2000.03 ± 0.0060.03 ± 0.006
 Cisplatin>2007.1 ± 0.035.8 ± 0.1
Ovarian cancer (A2780)
 Paclitaxel>2000.08 ± 0.010.1 ± 0.01
 Cisplatin>2000.2 ± 0.080.3 ± 0.01
Ovarian cancer (IGROV-1)
 Paclitaxel>2000.3 ± 0.060.3 ± 0.05
 Cisplatin>2001.2 ± 0.081.8 ± 0.05
Cervix uteri cancer (HeLa)
 Paclitaxel>2000.1 ± 0.0080.08 ± 0.007
 Cisplatin>2001.6 ± 0.031.4 ± 0.07
NSCLC (NCI-H460)
 Paclitaxel>2000.1 ± 0.020.09 ± 0.03
 Cisplatin>2001.3 ± 0.091.4 ± 0.1
Testicular teratocarcinoma (NTERA-2)
 Paclitaxel>2003.7 ± 0.33.2 ± 0.2
 Cisplatin>2000.3 ± 0.030.3 ± 0.03